- If you are wondering whether Chemed at around US$374 per share still reflects its underlying worth, the current valuation picture offers some clear signals to work through.
- The share price has pulled back recently, with a 2.4% decline over the past week, a 21.8% drop over the last 30 days, and a 38.3% decline over the past year. This may have shifted how investors see both risk and potential reward.
- Recent coverage has focused on Chemed's role in healthcare services and how sector wide sentiment can influence stocks that operate in essential service areas. This context helps frame whether the sharp share price moves are more about changing expectations for the sector or about company specific views.
- Chemed currently holds a valuation score of 5/6, which suggests that several key checks point to undervaluation. The rest of this article will break that down using different methods before ending with a broader way to think about what value really means for this stock.
Find out why Chemed's -38.3% return over the last year is lagging behind its peers.
Approach 1: Chemed Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting them back to a single present value.
For Chemed, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is $329.0 million, and analyst input plus extrapolated estimates point to free cash flow of $445.2 million in 2035. Simply Wall St uses analyst forecasts where available, then extends those projections over ten years.
Combining all those projected cash flows, the model arrives at an estimated intrinsic value of about $673.83 per share. Against a current share price around $374, the DCF output suggests Chemed is trading at roughly a 44.5% discount to this estimate using this method.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Chemed is undervalued by 44.5%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
Approach 2: Chemed Price vs Earnings
For profitable companies, the P/E ratio is a useful way to connect what you pay for each share with the earnings that support that price. It gives a quick sense of how many dollars of share price you are paying for each dollar of current earnings.
What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth potential and risk profile. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower, more cautious multiple.
Chemed currently trades on a P/E of 19.4x. That sits below both the Healthcare industry average of about 21.5x and the peer group average of 36.8x. This suggests the market is assigning a lower multiple than many comparable names. Simply Wall St’s proprietary Fair Ratio for Chemed is 24.7x. This Fair Ratio is designed to be a more tailored benchmark than simple peer or industry comparisons because it brings in factors like earnings growth expectations, profit margins, risk profile, industry and market capitalization.
Comparing Chemed’s current P/E of 19.4x with the Fair Ratio of 24.7x indicates that the shares are trading below that tailored estimate.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Chemed Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Chemed’s story together with your own revenue, earnings and margin assumptions, link that forecast to a Fair Value, and let you compare it to the current price inside Simply Wall St’s Community page. Narratives update automatically when new news or earnings arrive. For example, one Chemed Narrative might lean toward the higher US$580 fair value with stronger growth and margins, while another might sit closer to the US$400 view with more cautious assumptions. You can then see clearly how each story leads to a different Fair Value versus today’s market price.
Do you think there's more to the story for Chemed? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com